EMEA initiating dialogue with health technology assessment bodies
This article was originally published in SRA
Executive Summary
The European Medicines Agency is initiating a dialogue with health technology assessment bodies in the European Union with a view to standardising the criteria used in their respective assessments so that industry can get their products approved for both marketing and reimbursement. This was a much-discussed topic at the Drug Information Association’s 45th annual meeting in San Diego, US, on 21-25 June.